1. Home
  2. CLPR vs IMMP Comparison

CLPR vs IMMP Comparison

Compare CLPR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$3.50

Market Cap

51.8M

Sector

Real Estate

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.60

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
IMMP
Founded
2015
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.8M
58.2M
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
CLPR
IMMP
Price
$3.50
$0.60
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
65.2K
22.2M
Earning Date
05-11-2026
04-23-2026
Dividend Yield
11.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$109,997,000.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.82
N/A
52 Week Low
$2.83
$0.29
52 Week High
$4.61
$3.53

Technical Indicators

Market Signals
Indicator
CLPR
IMMP
Relative Strength Index (RSI) 64.32 39.53
Support Level $3.34 $0.29
Resistance Level $3.60 $1.89
Average True Range (ATR) 0.15 0.08
MACD 0.05 0.12
Stochastic Oscillator 90.41 40.56

Price Performance

Historical Comparison
CLPR
IMMP

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: